353 related articles for article (PubMed ID: 21196269)
1. Emerging metabolic targets in cancer therapy.
Zhao Y; Liu H; Riker AI; Fodstad O; Ledoux SP; Wilson GL; Tan M
Front Biosci (Landmark Ed); 2011 Jan; 16(5):1844-60. PubMed ID: 21196269
[TBL] [Abstract][Full Text] [Related]
2. Targeting cellular metabolism to improve cancer therapeutics.
Zhao Y; Butler EB; Tan M
Cell Death Dis; 2013 Mar; 4(3):e532. PubMed ID: 23470539
[TBL] [Abstract][Full Text] [Related]
3. Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells.
Bonelli M; Terenziani R; Zoppi S; Fumarola C; La Monica S; Cretella D; Alfieri R; Cavazzoni A; Digiacomo G; Galetti M; Petronini PG
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708306
[No Abstract] [Full Text] [Related]
4. Glycolysis Inhibitors for Anticancer Therapy: A Review of Recent Patents.
Sheng H; Tang W
Recent Pat Anticancer Drug Discov; 2016; 11(3):297-308. PubMed ID: 27087655
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1.
Kim JW; Gao P; Liu YC; Semenza GL; Dang CV
Mol Cell Biol; 2007 Nov; 27(21):7381-93. PubMed ID: 17785433
[TBL] [Abstract][Full Text] [Related]
6. Energy deregulation: licensing tumors to grow.
Garber K
Science; 2006 May; 312(5777):1158-9. PubMed ID: 16728625
[No Abstract] [Full Text] [Related]
7. Reversal of the glycolytic phenotype of primary effusion lymphoma cells by combined targeting of cellular metabolism and PI3K/Akt/ mTOR signaling.
Mediani L; Gibellini F; Bertacchini J; Frasson C; Bosco R; Accordi B; Basso G; Bonora M; Calabrò ML; Mattiolo A; Sgarbi G; Baracca A; Pinton P; Riva G; Rampazzo E; Petrizza L; Prodi L; Milani D; Luppi M; Potenza L; De Pol A; Cocco L; Capitani S; Marmiroli S
Oncotarget; 2016 Feb; 7(5):5521-37. PubMed ID: 26575168
[TBL] [Abstract][Full Text] [Related]
8. Shenmai Injection Supresses Glycolysis and Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant A549/DDP Cells via the AKT-mTOR-c-Myc Signaling Pathway.
Sun Y; Chen Y; Xu M; Liu C; Shang H; Wang C
Biomed Res Int; 2020; 2020():9243681. PubMed ID: 32685545
[TBL] [Abstract][Full Text] [Related]
9. Targeting pyruvate dehydrogenase kinase signaling in the development of effective cancer therapy.
Anwar S; Shamsi A; Mohammad T; Islam A; Hassan MI
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188568. PubMed ID: 34023419
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Aerobic Glycolysis Represses Akt/mTOR/HIF-1α Axis and Restores Tamoxifen Sensitivity in Antiestrogen-Resistant Breast Cancer Cells.
Woo YM; Shin Y; Lee EJ; Lee S; Jeong SH; Kong HK; Park EY; Kim HK; Han J; Chang M; Park JH
PLoS One; 2015; 10(7):e0132285. PubMed ID: 26158266
[TBL] [Abstract][Full Text] [Related]
11. The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance.
Huang X; Gan G; Wang X; Xu T; Xie W
Autophagy; 2019 Jul; 15(7):1258-1279. PubMed ID: 30786811
[TBL] [Abstract][Full Text] [Related]
12. Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K.
Courtnay R; Ngo DC; Malik N; Ververis K; Tortorella SM; Karagiannis TC
Mol Biol Rep; 2015 Apr; 42(4):841-51. PubMed ID: 25689954
[TBL] [Abstract][Full Text] [Related]
13. Glycometabolic adaptation mediates the insensitivity of drug-resistant K562/ADM leukaemia cells to adriamycin via the AKT-mTOR/c-Myc signalling pathway.
Zhang X; Ai Z; Chen J; Yi J; Liu Z; Zhao H; Wei H
Mol Med Rep; 2017 Apr; 15(4):1869-1876. PubMed ID: 28259993
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
Yang Z; Zhang SL; Hu X; Tam KY
Eur J Pharmacol; 2018 Nov; 838():41-52. PubMed ID: 30213498
[TBL] [Abstract][Full Text] [Related]
15. Targeting the PI3-kinase/Akt/mTOR signaling pathway.
Hassan B; Akcakanat A; Holder AM; Meric-Bernstam F
Surg Oncol Clin N Am; 2013 Oct; 22(4):641-64. PubMed ID: 24012393
[TBL] [Abstract][Full Text] [Related]
16. Metabolic phenotype of bladder cancer.
Massari F; Ciccarese C; Santoni M; Iacovelli R; Mazzucchelli R; Piva F; Scarpelli M; Berardi R; Tortora G; Lopez-Beltran A; Cheng L; Montironi R
Cancer Treat Rev; 2016 Apr; 45():46-57. PubMed ID: 26975021
[TBL] [Abstract][Full Text] [Related]
17. Cited2 is required for the maintenance of glycolytic metabolism in adult hematopoietic stem cells.
Du J; Li Q; Tang F; Puchowitz MA; Fujioka H; Dunwoodie SL; Danielpour D; Yang YC
Stem Cells Dev; 2014 Jan; 23(2):83-94. PubMed ID: 24083546
[TBL] [Abstract][Full Text] [Related]
18. Akt is efficiently activated by PIF-pocket- and PtdIns(3,4,5)P3-dependent mechanisms leading to resistance to PDK1 inhibitors.
Najafov A; Shpiro N; Alessi DR
Biochem J; 2012 Dec; 448(2):285-95. PubMed ID: 23030823
[TBL] [Abstract][Full Text] [Related]
19. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth.
Sun Q; Chen X; Ma J; Peng H; Wang F; Zha X; Wang Y; Jing Y; Yang H; Chen R; Chang L; Zhang Y; Goto J; Onda H; Chen T; Wang MR; Lu Y; You H; Kwiatkowski D; Zhang H
Proc Natl Acad Sci U S A; 2011 Mar; 108(10):4129-34. PubMed ID: 21325052
[TBL] [Abstract][Full Text] [Related]
20. Tumor cells switch to mitochondrial oxidative phosphorylation under radiation via mTOR-mediated hexokinase II inhibition--a Warburg-reversing effect.
Lu CL; Qin L; Liu HC; Candas D; Fan M; Li JJ
PLoS One; 2015; 10(3):e0121046. PubMed ID: 25807077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
